Global life sciences leader Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to deliver consistent contrast and streamline workflow across a variety of MR environments.

 

The updated clearance now allows MRXperion to operate with MRI scanners at field strengths up to 7 Tesla, giving radiology departments greater flexibility across diverse MR suite configurations. The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency.

 

“MRXperion already has a strong track record of delivering dependable imaging performance across clinical settings, and this clearance reinforces and expands on its established reputation as a flexible solution that supports coordinated, efficient workflows across MR systems,” said Jill Carbone, Vice President and Head of Radiology North America Product & Pipeline at Bayer. 

 

“The clearance also exemplifies our continued innovation in MR solutions to consistently meet the needs of today’s imaging providers.”

 

Bayer emphasized that MR systems operate across healthcare settings with widely differing technical and workflow demands. MRXperion is engineered to support this full spectrum, from routine clinical imaging to advanced research applications. The FDA clearance further strengthens Bayer’s integrated MR portfolio, which spans contrast media, injection systems, software, and workflow solutions.